3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
5
Lymphoid
2
Gynecologic
2
Plasma cell
1
Genitourinary
1
Classical hematology
1
Breast
1
Conditions
Ovarian Neoplasms
535
Uterine Cervical Neoplasms
249
Fallopian Tube Neoplasms
239
Endometrial Neoplasms
142
Carcinoma, Ovarian Epithelial
135
Breast Neoplasms
101
Neoplasms
74
Carcinoma, Non-Small-Cell Lung
70
Colorectal Neoplasms
53
Uterine Cervical Dysplasia
49
Papillomavirus Infections
49
Neoplasm Metastasis
48
Pancreatic Neoplasms
46
Melanoma
44
Uterine Neoplasms
43
Prostatic Neoplasms
41
Urinary Bladder Neoplasms
40
Lung Neoplasms
40
Stomach Neoplasms
38
Peritoneal Neoplasms
37
Recurrence
36
Carcinoma, Renal Cell
35
Triple Negative Breast Neoplasms
33
Head and Neck Neoplasms
32
Esophageal Neoplasms
31
Small Cell Lung Carcinoma
30
Sarcoma
28
Vulvar Neoplasms
26
Vaginal Neoplasms
24
Testicular Neoplasms
22
Interventions
rucaparib
1
olaparib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Pathologic Complete Response
×
Gynecologic
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts